Phase 3 trial suggests benefit of MDMA‐assisted therapy for PTSD
The Brown University Psychopharmacology Update August 1, 2021 DOI: 10.1002/pu.30752
Summary
AI-generated from the abstractAdding MDMA to manualized therapy for PTSD significantly improves symptoms and reduces functional impairment compared to placebo, based on a Phase 3 trial. No increase in adverse events, including suicidality, was observed with MDMA use. Results were published online May 10 in Nature Medicine.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Intervention | MDMA |
| Key finding | Adding MDMA to manualized therapy for PTSD resulted in significant symptom improvement and reduced functional impairment relative to placebo, with no increase in adverse events. |
Abstract
Adding 3,4‐methylenedioxymethamphetamine (MDMA) to manualized therapy for post‐traumatic stress disorder (PTSD) resulted in significant symptom improvement and reduced functional impairment relative to placebo in a Phase 3 trial. The researchers observed no increase in adverse events from use of MDMA, including no increase in suicidality. Study results were published online May 10 in Nature Medicine.